Viracta Therapeutics Inc
North American company
News & analysis
Times are shown in GMT-4, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
Viracta Therapeutics Inc is a clinical-stage, biomarker-directed precision oncology company focused on advancing new medicines for the treatment of virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma.
Latest VIRX News